US EditionBillionaire Mehta Brothers’ Torrent To Buy Stake In India’s JB Pharma In $1.4 Billion Deal
INDIA, JUN 29 – The Rs 25,689 crore deal will expand Torrent's portfolio into chronic diseases and ophthalmology and includes a mandatory open offer for 26% of JB Chemicals shares, the second-largest pharma acquisition in India.
- On June 29, 2025, Torrent Pharmaceuticals entered into definitive agreements to purchase a controlling interest in JB Chemicals & Pharmaceuticals in India, with the deal valued at ₹25,689 crore .
- The acquisition follows KKR's decision to sell its 46.39% stake via Tau Investment Holdings, with Torrent purchasing 26% more through a mandatory open offer and an additional 2.8% from employees.
- The deal will be executed in two phases, culminating in a merger where every 100 JB Pharma shares convert to 51 Torrent shares, subject to regulatory approvals from Indian authorities.
- Torrent Executive Chairman Samir Mehta expressed satisfaction with integrating JB Pharma’s legacy into Torrent’s operations, emphasizing this move as a foundation for the company’s future growth and strategic development.
- The acquisition diversifies Torrent’s platform with JB Pharma’s fast-growing Indian business and CDMO capabilities, aiming to strengthen market share and scale revenue and profitability in India and globally.
Insights by Ground AI
Does this summary seem wrong?
31 Articles
31 Articles
Torrent Pharma's Strategic Acquisition Boost
Torrent Pharma's Strategic Acquisition Boost In a significant move within the pharmaceutical sector, India's Torrent Pharmaceuticals announced its plan to acquire a 46.39% controlling stake in JB Chemicals and Pharmaceuticals. The stake is being purchased from the New York-based investment firm KKR.The acquisition, part of a merger plan outlined by the companies, represents a strategic effort to consolidate operations. The joint announcement fro…
·India
Read Full Article
Coverage Details
Total News Sources31
Leaning Left3Leaning Right6Center6Last UpdatedBias Distribution40% Center, 40% Right
Bias Distribution
- 40% of the sources are Center, 40% of the sources lean Right
40% Right
L 20%
C 40%
R 40%
Factuality
To view factuality data please Upgrade to Premium
